转移性结直肠癌患者临床特征与KRAS突变之间的关系缺失
Lack of Relationship Between Clinical Features and KRAS Mutations in Patients with Metastatic Colorectal Cancer.
作者信息
Ploquin Anne, Zerimech Farid, Escande Fabienne, Adenis Antoine, Giraud Claire, Gasnault Laurent, Bourgeois Vincent, Desauw Christophe, Hebbar Mohamed
机构信息
Department of Medical Oncology, University Hospital, Lille, France
Biomolecular platform, University Hospital, Lille, France.
出版信息
Anticancer Res. 2016 Aug;36(8):4233-6.
BACKGROUND/AIM: We previously identified three clinical predictive factors of efficacy of cetuximab-irinotecan. Here, we analyzed the clinical characteristics of patients with metastatic colorectal cancer (CRC) in order to detect potent correlations with KRAS mutations.
PATIENTS AND METHODS
We conducted a retrospective, multicenter study between 2008 and 2012. We included patients with metastatic colorectal adenocarcinomas, previously treated by irinotecan, and with an available KRAS mutation test.
RESULTS
We included 299 patients. The median age was 60 years; the median number of metastatic sites was 2. One hundred and eight patients (36.1%) had a previous objective response to irinotecan. The median interval between diagnosis and irinotecan discontinuation was 1.94 years. A KRAS mutation was detected in 133 patients (44.5%). In univariate and multivariate analyses, none of the assessed factors was associated with the presence of a KRAS mutation.
CONCLUSION
No easily clinically assessable parameter was significantly associated with KRAS mutations in patients with colorectal cancer.
背景/目的：我们之前确定了西妥昔单抗联合伊立替康疗效的三个临床预测因素。在此，我们分析了转移性结直肠癌（CRC）患者的临床特征，以检测与KRAS突变的潜在相关性。
患者与方法
我们在2008年至2012年期间进行了一项回顾性多中心研究。纳入的患者为转移性结直肠腺癌患者，此前接受过伊立替康治疗，且有可用的KRAS突变检测结果。
结果
我们纳入了299例患者。中位年龄为60岁；转移部位的中位数为2个。108例患者（36.1%）既往对伊立替康有客观反应。诊断与停用伊立替康之间的中位间隔时间为1.94年。133例患者（44.5%）检测到KRAS突变。在单因素和多因素分析中，所评估的因素均与KRAS突变的存在无关。
结论
在结直肠癌患者中，没有易于临床评估的参数与KRAS突变显著相关。
Zotero 插件